The 50% hemolytic concentration (HC50) determination is a quantitative in vitro assay that measures the exact concentration of a test substance required to lyse 50% of a standardized red blood cell suspension. As a cornerstone of hemocompatibility and hemolytic toxicity evaluation, this method supports pharmaceutical development, medical device biocompatibility testing, and the safety assessment of chemicals, botanical extracts, and venoms in accordance with ISO 10993-4 and related international standards. This article explains the technical principles, sample types, test items, methodologies, and typical applications of HC50 determination.
Technical Overview
The 50% hemolytic concentration, commonly abbreviated as HC50, is defined as the concentration of a test substance that produces 50% lysis of a defined population of erythrocytes under controlled experimental conditions. The assay quantifies the release of hemoglobin from disrupted red blood cells, which is directly proportional to the degree of hemolysis and can be measured spectrophotometrically at the absorption maximum of oxyhemoglobin, typically 540 to 545 nm.
Hemolysis occurs when a test substance damages or destabilizes the erythrocyte membrane, allowing intracellular hemoglobin to escape into the surrounding plasma or buffer. By exposing a standardized red blood cell suspension to a geometric series of test concentrations and plotting the percentage of hemolysis against the logarithm of concentration, a characteristic sigmoidal dose-response curve is obtained. Statistical curve-fitting methods such as probit analysis, logit transformation, or four-parameter logistic regression are then applied to interpolate the HC50 value, which is conventionally reported with 95% confidence intervals.
HC50 determination is widely referenced in hemocompatibility evaluation frameworks, including ISO 10993-4 for the selection of tests for interactions with blood, ASTM F756 for material-mediated hemolysis, and the corresponding GB/T 16886.4 standard. It should be distinguished from the CH50 assay, which measures complement activity in serum: although both assays use a 50% hemolysis endpoint, HC50 characterizes the hemolytic potency of a test substance, whereas CH50 quantifies the functional capacity of the complement system in a serum sample.
Testing Samples
Pharmaceutical and Biological Products
Injectable formulations, including small-molecule drugs, antibiotics, biological products, and plant-derived injections, are routinely evaluated for hemolytic potential before clinical use. Any substance intended for intravenous or intramuscular administration must be verified as non-hemolytic at therapeutic concentrations, and HC50 determination provides a quantitative margin-of-safety estimate.
Medical Device Extracts
Extracts of blood-contacting medical devices, prepared according to ISO 10993-12 extraction procedures, are tested to assess material-mediated hemolysis. Catheters, blood bags, dialysis membranes, stents, oxygenators, and infusion sets are typical examples where leachable substances may compromise red blood cell integrity.
Chemicals, Surfactants, and Nanomaterials
Surface-active agents, detergents, solubilizers, and engineered nanomaterials frequently exhibit membrane-disrupting properties. HC50 testing characterizes their hemolytic potency and supports concentration limits for formulations in which they serve as excipients or processing aids.
Natural Products, Venoms, and Toxins
Saponin-rich botanical extracts, snake venoms, bee venoms, bacterial hemolysins, and other pore-forming toxins are potent inducers of hemolysis. HC50 values serve as standardized potency metrics for batch-to-batch comparison, neutralization studies, and structure-activity investigations.
Serum Specimens for Complement Activity
In clinical immunology, serum samples are analyzed using the CH50 variant of the assay, in which antibody-sensitized sheep erythrocytes are lysed by the complement cascade present in the specimen. The result, expressed in hemolytic units per milliliter, aids in the diagnosis of complement deficiencies and immune complex diseases.
Testing Items
Typical quantitative outputs of the determination include:
- Percentage hemolysis at each graded test concentration, calculated against positive and negative controls
- The HC50 value with 95% confidence intervals, expressed in mass concentration (such as mg/mL) or activity units (U/mL)
- The hemolysis ratio of medical device extracts, with values exceeding 5% generally classified as hemolytic under GB/T 16886.4 and ISO 10993-4 evaluation principles
- CH50 serum complement activity in hemolytic units per milliliter for clinical specimens
- Dose-response parameters, including the slope of the response curve and the threshold concentration at the onset of detectable hemolysis
- Comparative hemolytic index between test batches or between a test article and a reference substance
Testing Methods
The most widely applied technique is the spectrophotometric hemolysis assay, performed as outlined below:
- Blood collection: fresh blood is drawn from healthy human, rabbit, or sheep donors into anticoagulant (heparin or citrate), and tested within a validated time window.
- Red blood cell preparation: erythrocytes are washed repeatedly with isotonic phosphate-buffered saline or physiological saline by centrifugation until the supernatant is clear, then diluted to a standardized suspension, commonly 2%.
- Sample dilution: the test substance is serially diluted in isotonic buffer to generate a geometric concentration series spanning the expected 0% to 100% hemolysis range.
- Controls: distilled water or a Triton X-100 solution serves as the positive control for complete hemolysis, while isotonic buffer serves as the negative control for spontaneous lysis.
- Incubation: equal volumes of erythrocyte suspension and test solutions are mixed and incubated at 37 degrees Celsius, typically for 30 to 60 minutes with gentle mixing.
- Separation: samples are centrifuged to pellet intact cells, and the hemoglobin content of the supernatant is determined by absorbance measurement at 540 to 545 nm.
- Calculation: hemolysis percentage equals (A sample minus A negative control) divided by (A positive control minus A negative control), multiplied by 100.
- Data analysis: the concentration-hemolysis curve is fitted by probit, logit, or four-parameter logistic models, and the HC50 is interpolated with its 95% confidence interval.
For serum complement activity determination, the CH50 assay employs antibody-sensitized sheep erythrocytes incubated with serial dilutions of patient serum. The von Krogh transformation is applied to linearize the sigmoidal dose-response relationship, and the dilution yielding 50% hemolysis is used to compute complement activity in hemolytic units per milliliter, with a reference interval of approximately 50 to 100 U/mL in most laboratories.
Quality assurance measures include erythrocyte concentration verification, hemolysis confirmation of positive controls exceeding 90%, background hemolysis in negative controls below 5%, replicate testing with acceptable precision, and verification of sample osmolality and pH, since hypotonic or acidic conditions can independently induce hemolysis and bias results.
Applications
HC50 determination is applied across multiple sectors of product development and safety evaluation:
- Preclinical safety assessment of injectable drugs and biological products, establishing hemolytic safety margins before first-in-human studies
- Quality control of plant-derived and traditional medicine injections, where the assay is a pharmacopoeial requirement for hemolysis and aggregation testing
- Biocompatibility evaluation of blood-contacting medical devices in conformity with ISO 10993-4, supporting regulatory submissions
- Safety profiling of cosmetic ingredients and personal care formulations intended for mucosal or compromised-skin exposure
- Standardization and potency assignment of venoms, hemolysins, and saponin extracts used in research and antivenom development
- Characterization of surfactants and excipients for formulation science, guiding the selection of low-hemolysis solubilizers
- Clinical laboratory diagnosis of complement system deficiencies and monitoring of complement-activating conditions through CH50 measurement
- Environmental and nanomaterial toxicology, where hemolytic activity indicates membrane-disrupting potential of engineered particles
FAQ
What is the difference between HC50 and CH50?
HC50 refers to the concentration of a test substance that lyses 50% of red blood cells and characterizes the hemolytic potency of that substance. CH50, in contrast, measures the dilution or quantity of serum complement that lyses 50% of antibody-sensitized erythrocytes and is used to evaluate complement system function. The two assays share a similar endpoint logic but address entirely different questions.
Which standards govern HC50 determination?
The principal frameworks include ISO 10993-4 for blood interaction testing of medical devices, ASTM F756 for material hemolysis assessment, and GB/T 16886.4 as the corresponding national adoption. Pharmacopoeial hemolysis test chapters additionally govern injectable product evaluation. Accredited third-party laboratories typically conduct these assays under GLP or ISO/IEC 17025 quality systems.
What blood sources are acceptable for the assay?
Human, rabbit, and sheep blood are the most commonly used sources. The choice depends on the assay purpose: rabbit blood is customary for medical device hemolysis testing, human blood better predicts clinical relevance for pharmaceuticals, and sheep erythrocytes are standard for complement CH50 assays because they are optimal targets for antibody sensitization.
How is the HC50 value calculated from raw data?
Absorbance readings are converted to hemolysis percentages using the positive and negative control values, the percentages are plotted against log concentration, and a sigmoidal model is fitted. The concentration corresponding to 50% hemolysis on the fitted curve is reported as the HC50, together with 95% confidence intervals derived from the regression.
What result indicates an acceptable safety profile?
Interpretation is product-specific. For medical device extracts, hemolysis below 5% is generally considered acceptable. For injectable products, the HC50 should greatly exceed the intended clinical plasma concentration, and the safety margin is evaluated case by case in relation to the maximum administered dose.
How long does a typical determination take?
The bench work, including blood preparation, incubation, and absorbance measurement, is usually completed within one day. Turnaround time from sample receipt to final report typically ranges from five to ten working days, depending on the number of concentrations, replicate design, and any preliminary range-finding studies.
